ArticleJCEM case reports2026
Diffuse osteosclerosis in a patient with systemic mastocytosis.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosclerosis refers to an abnormal increase in bone density resulting from excessive bone formation and/or reduced bone resorption. We present a case of a 31-year-old woman with acute-on-chronic abdominal pain, flushing, and diarrhea. Diffuse, mottled sclerosis involving the entire axial and appendicular skeleton was incidentally identified on imaging. Diagnostic investigations for osteosclerosis revealed a raised tryptase, leading to a bone marrow and trephine analysis. This demonstrated abnormally spindle-shaped mast cells, more than 15 in a group, with positive staining for tryptase which was consistent with systemic mastocytosis (SM). In the absence of "C" findings, a diagnosis of indolent SM complicated by diffuse osteosclerosis was made. Treatment with a histamine type-2 receptor antagonist provided mild symptomatic relief. In this report, we discuss the differential causes of osteosclerosis and the pathogenesis of bone manifestations related to SM, along with subtype-specific SM treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.